Istiratumab
Istiratumab
Istiratumab (pronounced as is-ti-ra-tu-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets specific proteins on cancer cells to inhibit their growth and spread.
Etymology
The name "Istiratumab" is derived from the International Nonproprietary Naming (INN) system for monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, while the "tira" infix suggests it targets the tumors.
Mechanism of Action
Istiratumab works by binding to specific proteins on the surface of cancer cells. This binding action can block the signals that tell the cancer cells to grow and divide, effectively slowing or stopping the progression of the disease.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight cancer, infections, and other diseases.
- Tumor: An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
See Also
External links
- Medical encyclopedia article on Istiratumab
- Wikipedia's article - Istiratumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski